Regeneron Pharmaceuticals (NASDAQ:REGN) said Monday that partner Hansoh Pharmaceutical Group Company Limited reported ...

Hansoh’s olatorepatide achieved 19% weight loss at 48 weeks in a Phase 3 trial in China, handing partner Regeneron a glimmer ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Asia has lagged the West on GLP‑1 weight‑loss drugs, but rising obesity, cheaper generics and supportive health systems in ...

A new, strange phenomenon called the “plastic eating” trend for weight loss is gaining momentum in China on TikTok. According to clips doing the rounds on the internet, people, especially youngsters, ...

China approves Pfizer’s GLP-1 weight-loss drug, expanding competition in the booming obesity treatment market and ...

Ecnoglutide is distinguished by its selective activation of the cAMP signalling pathway, reducing β-arrestin recruitment.

Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the ...

Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks ...

Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for ...

Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed ...